GlassScriptPhysician profile
Joseph Vitoulis
NPI 1154402030
$2,508.80
in general payments reported to CMS, 2019-2025
29 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,113 · 2022: $252 · 2023: $227 · 2024: $498 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $439.04 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $411.74 | 2021-2024 | Vraylar |
| Lilly USA, LLC | $288.74 | 2021-2025 | Jardiance |
| Medtronic, INC. | $174.94 | 2023 | Cd Horizon Spinal System |
| Novo Nordisk INC | $172.28 | 2021-2022 | |
| Philips North America LLC | $165.33 | 2024 | (Ck7) Extended Holter, (Ck6) Holter |
| Alkermes, INC. | $158.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.55 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.71 | 2021 | |
| Gilead Sciences, INC. | $55.48 | 2021 | |
| Amarin Pharma, INC. | $54.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $46.96 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $41.46 | 2021 | |
| Merck Sharp & Dohme LLC | $38.62 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.49 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.24 | 2021 | |
| Glaxosmithkline, LLC. | $21.66 | 2025 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $17.92 | 2022 | |
| Indivior INC. | $17.91 | 2022 | |
| Shield Therapeutics INC | $17.69 | 2022 | |
| Mannkind Corporation | $17.29 | 2022 | |
| Avanos Medical | $16.71 | 2021 | |
| Heartflow, INC. | $15.78 | 2024 | |
| Jazz Pharmaceuticals INC. | $15.58 | 2021 | |
| Orexo US, INC. | $15.06 | 2021 | |
| Currax Pharmaceuticals LLC | $13.76 | 2024 | Contrave |
| Daiichi Sankyo INC. | $13.64 | 2021 | |
| Medicomp INC | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vitoulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.